Rare lung disease study aims to uncover key health markers
NCT ID NCT05685186
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study observed 31 adults with primary ciliary dyskinesia (PCD), a rare lung condition, along with healthy volunteers. Researchers measured lung function, mucus clearance, and lung structure using tests like spirometry and CT scans. The goal was to better understand the disease and establish normal values for future research.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help researchers better understand how primary ciliary dyskinesia affects adults, potentially guiding future treatments.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve health. Results may not apply to all patients with PCD.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
31 people
The number who actually took part.
- Started
-
Mar 2023
- Finished
-
Jun 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Individuals with a diagnosis of Primary Ciliary Dyskinesia and healthy volunteers
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * PCD diagnosis with confirmation of 2 identified pathogenic genetic variants within 1 of the following ultrastructure variants: * DNAI1 ODA defect * Other ODA defect * IDA - MTD defect * RS defect * Informed consent Exclusion Criteria: * Are a current smoker (e-cigarette, tobacco, or marijuana) * Are a former smoker who discontinued smoking \<1 year prior to enrollment or has a cumulative 1+ pack-year smoking history * Have a recent stable forced expiratory volume in one second (FEV1) \<35% predicted * Have contraindications for MRI studies (implanted devices/materials; inability to tolerate; claustrophobia or severe anxiety that would preclude MRI/imaging) * Have had a significant clinical radiation exposure (as determined by the investigator) within the past 6 months. Potential participants who have had a chest CT within the past 6 months may be eligible to be enrolled and their clinical CT will be utilized as the baseline for this study * Are pregnant or breastfeeding * Have any comorbidities likely to impact lung function (e.g., complex congenital heart disease, severe scoliosis, diseases involving immune dysregulation, lung transplantation, lung lobectomy, end-stage renal disease, or poor overall health status).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Primary ciliary dyskinesia are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could exercise be a new way to clear lungs in PCD?
- Can better testing unlock the secrets of a rare lung disease?
- Tiny hairs in fallopian tubes may hold key to ectopic pregnancy
- Could a simple saltwater mist make breathing easier for lung patients?
- 300-Patient study aims to unlock secrets of rare lung disease
- Global study to uncover hidden ENT patterns in rare lung disease